Sarepta Prospectus FORWARD-LOOKING STATEMENTSThis prospectus...

Sarepta Prospectus

FORWARD-LOOKING STATEMENTS
This prospectus supplement and the SEC filings that are incorporated by reference into this prospectus supplement contain or incorporate by
reference “forward-looking statements.” You can generally identify these forward-looking statements by forward-looking words such as “believe,”
“anticipate,” “expect,” “intend,” “plan,” “will,” “may,” “estimate,” “could,” “continue,” “ongoing,” “predict,” “potential,” “likely,” “seek” and other
similar expressions, as well as variations or negatives of these words. You should read these statements carefully because they discuss future
expectations, contain projections of future results of operations or financial condition, or state other “forward-looking” information. These statements
relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These
forward-looking statements include, but are not limited to:

• the expected or potential impact of the ongoing COVID-19 pandemic on our business, including our commercial sales, ongoing and
planned clinical trials, manufacturing and operations;
• our belief that our proprietary technology platforms and collaborations can be used to develop potential therapeutic candidates to treat a
broad range of diseases;
• our expectation that our partnerships with manufacturers will support our clinical and commercial manufacturing capacity for our microdystrophin
Duchenne muscular dystrophy gene therapy programs and Limb-girdle muscular dystrophy programs, while also acting as a
manufacturing platform for potential future gene therapy programs, and our belief that our current network of manufacturing partners are
able to fulfil the requirements of our commercial plan;
• our plan to continue building out our network for commercial distribution in jurisdictions in which our products are approved;
• estimated timelines and milestones for fiscal years 2021 and beyond, including announcing additional results from Study 102 in the first
quarter of 2022, completing good manufacturing practice product for SRP-9003 in 2021 and seeking FDA confirmation in 2021 to initiate
our SRP-9003 pivotal trial;
• our plan to expand our pipeline through internal research and development and through strategic transactions;
• the timely completion and satisfactory outcome of our post-marketing requirements and commitments, including verification of a clinical
benefit for our products in confirmatory trials;
• our plan to evaluate future engagement with the European Medicines Agency on potential next steps for EMA approval of our products;
• our ability to further secure long-term supply of our commercial products and our product candidates to satisfy our planned commercial,
early access programs and clinical needs;
• the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business, as well as the
development of our product candidates and our financial and contractual obligations;
• the possible impact of any competing products on the commercial success of our products and our product candidates and our ability to
compete against such products;
• our ability to enter into research, development or commercialization alliances with universities, hospitals, independent research centers,
non-profit organizations, pharmaceutical and biotechnology companies and other entities for specific molecular targets or selected disease
indications and our ability to selectively pursue opportunities to access certain intellectual property rights that complement our internal
portfolio through license agreements or other arrangements;
• our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic
arrangements and transactions we have entered into or may enter into